News for Addex Therapeutics Ltd (ADXN.SW)

Trading of Addex Therapeutics (ADXN) shares has recommenced after a brief pause. Investors are now able to engage with this company's market activities once aga

Trading for Addex Therapeutics (ADXN) Ltd ”“ ADR has been temporarily suspended due to a volatility trading pause. This halt is intended to address heightened

Cash Balance: CHF2.8 million as of March 31, 2025.Cash Runway: Expected to last through mid-2026.Continuing R&D Expenses: CHF0.1 million, primarily related to

Jun 19, 2025 / 02:00PM GMTTim Dyer - Addex Therapeutics Ltd - Chief Executive Officer, Co-Founder, Member of the Executive Management, Director Hello, everyone.

Addex Therapeutics (ADXN) has revealed promising findings regarding the anti-tussive effectiveness of its innovative gamma-aminobutyric acid sub-type B receptor

Addex Therapeutics, known by its ticker ADXN, has entered into a strategic partnership with Sinntaxis AB. This collaboration focuses on an exclusive license con

Series A Financing: USD65 million raised for Neurosterix, led by Perceptive Advisors.Cash Received: CHF5 million in cash from the Neurosterix transaction.Equit

Addex Therapeutics Ltd (NASDAQ:ADXN) Q4 2024 Earnings Conference Call April 25, 2025 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board Director...

Addex Therapeutics (ADXN) disclosed that it has reacquired all development and commercialization rights to ADX71149 after the termination of its collaboration w

Revenue: CHF0.1 million in Q3 2024, compared to CHF0.3 million in Q3 2023.R&D Expenses: CHF0.2 million in Q3 2024, decreased by CHF0.3 million from Q3 2023.G&A

Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board Director...

Texas-based Genprex, Inc. (GNPX), a clinical-stage gene therapy company is up over 103 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of iRhythm Technologies, Inc. IRTC rose sharply in today's pre-market trading after the company announced that it was granted FDA clearance for its 510(k...

Series A Financing: USD 63 million led by Perceptive Advisors.Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest.Milestone Payments: Up to

Sep 30, 2024 / 02:00PM GMTTim Dyer - Addex Therapeutics Ltd - Chief Executive Officer, Co-Founder, Member of the Executive Management, Director Hello, everyone.

Earnings call: Addex Therapeutics reports half-year financials and R&D updates

Addex Therapeutics Ltd (NASDAQ:ADXN) Q2 2024 Earnings Conference Call September 30, 2024 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board...

California-based Bolt Projects Holdings, Inc. (BSLK) is up over 103 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.02%